Cleveland Clinic | Strategic Alliance Partners

September 25, 2023

Closing out their program on multiple myeloma, expert panelists consider the role of holistic and multidisciplinary care when managing patients within the current paradigm.

September 25, 2023

Continuing its discussion on clinical trials in multiple myeloma, the panel emphasizes the impact that data may have on the real-world treatment landscape.

September 18, 2023

Key opinion leaders in multiple myeloma management elucidate the value of clinical trials and share enthusiasm for improving enrollment when possible.

September 18, 2023

A focused discussion on the regulatory aspects of drug testing and approval, globally, with respect to the setting of multiple myeloma management.

September 11, 2023

Expert panelists consider best methods in educating patients on their options for therapy following a diagnosis of multiple myeloma.

September 11, 2023

Comprehensive insight to disparities that may impact a patient’s access to therapy for multiple myeloma and how these may be overcome.

September 04, 2023

Panelists share a brief discussion on the current treatment armamentarium available to patients with newly diagnosed multiple myeloma.

September 04, 2023

Experts in multiple myeloma management consider essential tests that aid in the diagnosis and treatment of newly presenting patients.

September 01, 2023

Brian Gastman MD, discusses how findings from CheckMate76K contributed to the rationale for a biomarker analysis in that trial’s patient population, key findings from this biomarker analysis, and how these findings may inform further research regarding the benefits of immunotherapy in earlier-stage disease.

September 01, 2023

Aaron T. Gerds, MD, PhD, expands on the potential role of momelotinib in the treatment of patients with myelofibrosis who present with anemia, details the data from MOMENTUM, and explains what FDA approval of momelotinib could mean for the treatment of this patient population.

August 25, 2023

Logan Roof, MD, discusses the importance of investigating demographic disparities that exist in lung cancer mortality, expands on the results of the population-based CDC database analysis, and discusses potential next steps to address these disparities in the future.

August 22, 2023

Shilpa Gupta, MD, expands on the updated results from EV-103 in patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin, and details the next steps for investigating the combination of enfortumab vedotin plus pembrolizumab in the ongoing phase 3 EV-302 trial.

August 21, 2023

Shared insight from key opinion leaders on educational resources made available to physicians and patients, respectively, regarding multiple myeloma management.

August 21, 2023

Opening its discussion on key unmet needs in multiple myeloma management, a panel of experts discuss key challenges faced when diagnosing patients with multiple myeloma and review the impact of having a multidisciplinary care team.

July 27, 2023

Logan Roof, MD, discusses findings from a study investigating trends in lung cancer mortality across different sociodemographic populations and locations in the United States between 1999 and 2020.

July 20, 2023

Megan Kruse, MD, offers advice to community oncologists treating HER2+ metastatic breast cancer and discusses unmet needs in the treatment landscape.

July 13, 2023

Shilpa Gupta, MD, discusses the enrollment criteria used for the phase 1/2 EV-103 trial in patients with locally advanced or metastatic urothelial carcinoma, and highlights next steps for the investigation of the frontline combination of enfortumab vedotin and pembrolizumab in the phase 3 EV-302 trial.

July 13, 2023

An overview of agents and treatment strategies currently being investigated in HER2+ metastatic breast cancer.

July 13, 2023

Megan Kruse, MD, discusses the HER2CLIMB-02 study and the impact it may have on the HER2+ metastatic breast cancer treatment landscape.

July 12, 2023

Brian Gastman, MD, discusses results from a biomarkers analysis of patients with stage IIB/C melanoma in the phase 3 CheckMate76K trial.